LoginSignup
Gilead Sciences logo

Gilead Sciences Stock

StockStock
ISIN: US3755581036
Ticker: GILD
US3755581036
GILD

Price

Historical dividends and forecast

All dividend data

Gilead Sciences has so far distributed $2.31 in 2024. The next dividend will be paid on 30.12.2024

$2.514

CHART BY

Frequently asked questions

What is Gilead Sciences's market capitalization?

The market capitalization of Gilead Sciences is $120.90B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Gilead Sciences's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Gilead Sciences is 1,155.26. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Gilead Sciences?

Gilead Sciences's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.084. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Gilead Sciences's stock?

Currently, 29 analysts cover Gilead Sciences's stock, with a consensus target price of $81.21. Analyst ratings provide insights into the stock's expected performance.

What is Gilead Sciences's revenue over the trailing twelve months?

Over the trailing twelve months, Gilead Sciences reported a revenue of $28.30B.

Is Gilead Sciences paying dividends?

Yes, Gilead Sciences is paying dividends. The next payment is scheduled for 30.12.2024, with an expected amount of .

What is the EBITDA for Gilead Sciences?

Gilead Sciences's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $13.51B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Gilead Sciences?

Gilead Sciences has a free cash flow of $6.67B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Gilead Sciences's stock?

The 5-year beta for Gilead Sciences is 0.20. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Gilead Sciences have, and what sector and industry does it belong to?

Gilead Sciences employs approximately 18,000 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Gilead Sciences's shares?

The free float of Gilead Sciences is 1.24B. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $120.90B

5Y beta

 0.20

EPS (TTM)

 $0.084

Free Float

 1.24B

P/E ratio (TTM)

 1,155.26

Revenue (TTM)

 $28.30B

EBITDA (TTM)

 $13.51B

Free Cashflow (TTM)

 $6.67B

Pricing

1D span
$94.08$98.11
52W span
$62.07$98.90

Analyst Ratings

The price target is $81.21 and the stock is covered by 29 analysts.

Buy

11

Hold

17

Sell

1

Information

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

18,000

Biotechnology & Drugs

Health Care

Identifier

ISIN

US3755581036

Primary Ticker

GILD

Knockouts

Join the conversation
Sign upLogin